
Opinion|Videos|January 20, 2025
Patient Selection for Teplizumab and Infusion Process
Panelists discuss how patient selection for teplizumab therapy requires careful screening for autoantibody positivity and preserved C-peptide function, followed by a 14-day outpatient infusion process that needs close monitoring for cytokine release syndrome and other potential adverse effects.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
ACOG Releases New Guidance on HIV Screening and Prevention
2
2026 Dyslipidemia Guideline Expands Statin Eligibility to 21.5 Million More US Adults
3
From Amyloid Clearance to Daytime Function: Why Sleep Quality Matters for Brain Health
4
FDA Approves First Oral PCSK9 Inhibitor to Reduce LDL-C in Adults With Hypercholesterolemia
5































































































































































